ALKS 2680 Dose 3

Phase 3

AAlkermes, Inc.

ALKS 2680 Dose 3 is one of 3 therapeutic programs targeting Narcolepsy Type 2. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Narcolepsy Type 2Recruiting

Narcolepsy Type 2Phase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Narcolepsy Type 2

#DrugCompanyPhaseTrials

ALKS 2680 Dose 1

AAlkermes, Inc.

Phase 3

1 2

ALKS 2680 Dose 2

AAlkermes, Inc.

Phase 3

1 3

ALKS 2680 Dose 3

AAlkermes, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Narcolepsy Type 2

NCT07502443

Clinical

Trials by Indication[1]

Narcolepsy Type 21 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)

Recruiting·AAlkermes, Inc.·Phase 3·NCT07502443·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALKS 2680 Dose 3. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ALKS 2680 Dose 3. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alkermes, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAlkermes, Inc.

ALKS 2680 Dose 3

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Narcolepsy Type 21 trial

References

Drug Info

Quick Facts

Related News